Screener
Tango Therapeutics TNGX Operating Income
Discontinued — last reported Q1 '26
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 33,534 | 36,442 |
| General and administrative | 15,235 | 11,480 |
| Total operating expenses | 48,769 | 47,922 |
| Loss from operations | (48,769) | (42,530) |
| Other income: | ||
| Interest income | 2,177 | 1,614 |
| Other income, net | 1,079 | 1,074 |
| Total other income, net | 3,256 | 2,688 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's operating income?
- Tango Therapeutics (TNGX) reported operating income of -$48.77M in Q1 2026.
- How has Tango Therapeutics's operating income changed year-over-year?
- Tango Therapeutics's operating income decreased by 14.7% year-over-year, from -$42.53M to -$48.77M.
- What is the long-term trend for Tango Therapeutics's operating income?
- Over 4 years (2021 to 2025), Tango Therapeutics's operating income has grown at a 17.6% compound annual growth rate (CAGR), from -$58.19M to -$111.29M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Tango Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude